Researchers from the University of Gothenburg and the University of Copenhagen reviewed evidence on obesity and type 2 diabetes medications like semaglutide and tirzepatide, noting links to reduced dementia risk in patient records and animal learning benefits. However, clinical trials like Novo Nord